Clinical outcomes and safety of tocilizumab in severe fever with thrombocytopenia syndrome: a retrospective multicenter cohort study
Frontiers in Cellular and Infection Microbiology · 2026
DOI: 10.3389/fcimb.2026.1894849 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Quanman Hu und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Public Health, Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Severe Fever with Thrombocytopenia Syndrome, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick - borne zoonotic infectious disease. Severe SFTS cases exhibit an extremely high fatality rate, but there remain no effective clinical treatments.
Methods
Propensity Score Matching (PSM) and logistic regression analysis were used to assess the efficacy, safety, and baseline factors influencing patient prognosis of tocilizumab in the treatment of SFTS.
Results
A total of 833 SFTS cases were included, of whom 171 received tocilizumab. After PSM, a higher recovery rate was observed in the tocilizumab group than in the control group (76.61% vs 67.70%, P = 0.039). However, the between-group difference in in-hospital mortality did not reach statistical significance after matching (16.96% vs 15.22%, P = 0.322). Regarding selected adverse events (AEs) such as co-infection, the between-group differences did not reach statistical significance; these represent observed differences in retrospectively recorded data and should not be interpreted as evidence of safety. Multivariable logistic regression showed that age ≥ 65 years, vasopressor therapy, platelet transfusion, and Ct value were associated with prognosis among tocilizumab-treated patients, with vasopressor use and platelet transfusion likely reflecting disease severity rather than independent causal determinants.
Conclusion
In this retrospective cohort, after PSM, tocilizumab use was associated with a higher recovery rate in SFTS patients, although the between-group difference in in-hospital mortality did not reach statistical significance. Observed differences in selected AEs were based on retrospectively recorded data and should not be interpreted as evidence of safety. Given the exploratory nature, prospective studies are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Public Health, Zhengzhou University, Zhengzhou, China.
- Huaiyang Disease Control and Prevention Center, Zhoukou, China.
- Disease Control and Prevention Center, Xinyang, China.
Zitieren
APA
Hu, Q., Jin, Y., Wei, Y., Chen, J., Hu, Y., Yang, Y., Zhang, L., Chen, S., & Duan, G. (2026). Clinical outcomes and safety of tocilizumab in severe fever with thrombocytopenia syndrome: a retrospective multicenter cohort study. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1894849
Vancouver
Hu Q, Jin Y, Wei Y, Chen J, Hu Y, Yang Y, et al. Clinical outcomes and safety of tocilizumab in severe fever with thrombocytopenia syndrome: a retrospective multicenter cohort study. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1894849
BibTeX
@article{Hu2026,
author = {Hu, Quanman and Jin, Yehan and Wei, Yaming and Chen, Jundong and Hu, Yan and Yang, Yanyan and Zhang, Li and Chen, Shuaiyin and Duan, Guangcai},
title = {Clinical outcomes and safety of tocilizumab in severe fever with thrombocytopenia syndrome: a retrospective multicenter cohort study},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
doi = {10.3389/fcimb.2026.1894849}
}
EUVIMED